-
公开(公告)号：US20220089704A1
公开(公告)日：2022-03-24
申请号：US17288445
申请日：2019-10-28
Applicant: Biogen MA Inc. , National Research Council of Canada
Inventor： Benjamin A. Smith , Andreas Lehmann , Thomas O. Cameron , R. Blake Pepinsky , Dingyi Wen , Graham K. Farrington , Gopalan Raghunathan , Nels E. Pederson , Danica Stanimirovic , Traian Sulea , Arsalan S. Haqqani
Abstract: Featured are compositions comprising humanized and engineered variants of an antibody variable domain (e.g., FC5), chimeric molecules comprising same, compositions comprising same, and uses thereof.
-
32.发明申请公开(公告)号：US20220034907A1
公开(公告)日：2022-02-03
申请号：US17299660
申请日：2019-12-03
Applicant: Biogen MA Inc.
Inventor： Toby Arlo FERGUSON , Danielle LeeZetta GRAHAM , Steve Sang-Woo HAN , Alexander Reid Vincent MCCAMPBELL , Giulio SRUBEK-TOMASSY
IPC: G01N33/68 , C12N15/113 , A61P25/28 , A61K31/7115
Abstract: In one aspect, the invention provides a method for alleviating a symptom in a patient with amyotrophic lateral sclerosis, comprising administering an efficacious therapeutic that is efficacious to the patient, the efficacious therapeutic, when administered to the patient, resulting in a level of a neurofilament protein in a biological sample of the patient that is lower than a level of neurofilament protein in a patient with amyotrophic lateral sclerosis not administered the therapeutic. In some embodiments, the patient is currently being administered with or has formerly been administered with either a non-efficacious therapeutic or a therapeutic that is different than the efficacious therapeutic.
-
公开(公告)号：US20210387972A1
公开(公告)日：2021-12-16
申请号：US17283301
申请日：2019-10-15
Applicant: BIOGEN MA INC.
Inventor： Fengmei ZHENG , Anton PETERSON , Kalyan VASUDEVAN , Chaomin LI , Daniel B. PATIENCE , Yiqing LIN
IPC: C07D405/14
Abstract: Provided are crystalline forms of (R)-1-(tert-butyl)-N-(8-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-2-(oxetan-3-yl)-2,3,4,5-tetrahydro-1H-benzo[c]azepin-5-yl)-1H-1,2,3-triazole-4-carboxamide, pharmaceutical compositions, methods of use and methods of making thereof.
-
34.发明申请公开(公告)号：US20210363259A1
公开(公告)日：2021-11-25
申请号：US16640422
申请日：2018-08-22
Applicant: Biogen MA Inc.
Inventor： Tia Brie Estey , Geetha Govindan , Sonal Saluja , Kapil Gupta , Margaret McGrath
IPC: C07K16/28 , A61K47/18 , A61K47/26 , A61K31/4418 , A61K31/496 , A61K47/12 , A61K47/20
Abstract: Formulations and dosage regimens of an anti-αvβ6 antibody or αvβ6-binding fragment thereof are provided. These formulations find use in the treatment of e.g., fibrosis (e.g., idiopathic pulmonary fibrosis), acute lung injury, and acute kidney injury.
-
公开(公告)号：US20210324095A1
公开(公告)日：2021-10-21
申请号：US17361393
申请日：2021-06-29
Applicant: UCB BIOPHARMA SRL , BIOGEN MA INC.
Inventor： RUTH OLIVER , MIREN ZAMACONA
IPC: C07K16/28 , A61K39/395
Abstract: The present invention relates to a method of treating an autoimmune or inflammatory disease or a neurodegenerative disease with an antibody to CD154.
-
Patent Agency Ranking
公开(公告)号：US20210315854A1
公开(公告)日：2021-10-14
申请号：US17321788
申请日：2021-05-17
Applicant: Biogen MA Inc.
Inventor： Mark Novas , Rui (Ray) Zhang
Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
-
公开(公告)号：US20210309719A1
公开(公告)日：2021-10-07
申请号：US17216769
申请日：2021-03-30
Applicant: Biogen MA Inc.
Inventor： Kevin Maloney , Ke Gong , Roy Alston
Abstract: Aspects of the invention are directed to arginine-free polypeptide-containing compositions and methods for treating disorders associated with inflammation or the autoimmune response. In particular, the polypeptide is etanercept.
-
公开(公告)号：US20210301002A1
公开(公告)日：2021-09-30
申请号：US17182426
申请日：2021-02-23
Inventor： Jeffrey L. Bennett , Richard M. Ransohoff , Fumitaka Shimizu , Kristin L. Schaller
Abstract: This disclosure provides anti-HSPA5 antibodies. Also featured is a method for delivering an agent into the brain, spinal cord, or other component of the central nervous system. In addition, methods of identifying a human subject at risk of relapse of neuromyelitis optica (NMO) or neuropsychiatric systemic lupus erythematosus (NP-SLE) are disclosed, as are methods of determining the severity of an attack of NMO or NP-SLE, and methods of diagnosing NP-SLE.
-
公开(公告)号：US20210300946A1
公开(公告)日：2021-09-30
申请号：US17265986
申请日：2019-08-13
Applicant: BIOGEN MA INC.
Inventor： Felix Gonzalez Lopez de Turiso
IPC: C07D498/22 , C07D519/00
Abstract: Provided are compounds of Formula (I′), including compounds of Formulas (I), (II), (III), (IIIA) and (IIIB), wherein L, R1, R3 and n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and production. These compounds can be useful, e.g., in the treatment of disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1).
-
公开(公告)号：US20210277111A1
公开(公告)日：2021-09-09
申请号：US17127324
申请日：2020-12-18
Applicant: Biogen MA Inc.
Inventor： Diego Cadavid , Sha Mi
IPC: C07K16/28 , A61K38/21 , A61K39/395 , A61K45/06
Abstract: Methods, compositions and kits are described herein useful for detecting and/or treating a CNS demyelinating disease.
-
-
-
-
-
-
-
-
-
Search Results
587
records
(took 0.025 seconds)
